Company Overview - Century Communities operates in 16 states and over 45 markets across the U S [9] - The company reported revenues of $4 2 billion for the last twelve months ending in Q3 2025 [14] - As of September 30, 2025, the company has 62,239 lots [14] Financial Performance & Growth - Total revenues increased by 64% from $2 5 billion in 2019 to $4 2 billion in LTM Q3 2025 [25] - EBITDA increased by 78% from $207 million in 2019 to $369 million in LTM Q3 2025 [25] - Book Value Per Share increased by 173% from $32 11 in 2019 to $87 74 in Q3 2025 [25] - Net Income increased by 90% from $113 million in 2019 to $214 million in LTM Q3 2025 [25] - Home sale deliveries increased by 32% from 8,000 in 2019 to 10,555 in LTM Q3 2025 [25] - The company repurchased approximately 6 2% of shares outstanding at the beginning of the year [23] Business Strategy & Operations - 94% of total company home deliveries are priced below FHA limits [30] - 99% of total company home deliveries are spec builds [32] - The company maintains a significant liquidity position of $836 million [43] - Financial Services revenues were $88 million with pretax income of $20 million in LTM 3Q 2025 [47]

Lam Research Corporation September quarter 2025 financial results October 22, 2025 Cautionary statement regarding forward-looking statements This presentation and the accompanying discussion contain "forward-looking statements" under U.S. securities laws. Forward-looking statements include any statements that are not statements of historical fact. Examples of forward-looking statements include, but are not limited to: (1) anticipated business, balance sheet, cash flow and financial measures and results and ...

Third Quarter 2025 Results Christian Klein, CEO Dominik Asam, CFO October 22, 2025 Christian Klein CEO Q3 was a great quarter 4,351 (+27%) 4,708 (+27%) 4,993 (+26%) 5,130 (+28%) 5,290 (+27%) 3,209 (+28%) 3,458 (+29%) 3,745 (+30%) 3,856 (+31%) 3,972 (+28%) Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Cloud revenue in € millions (yoy @cc) Cloud gross profit in € millions (yoy @cc) Current cloud backlog € millions 18,839 ▲ +23% (+27% @cc) Cloud revenue € millions 5,290 ▲ +22% (+27% @cc) Cloud ERP Suite revenue € millions 4,5 ...

Q3 2025 Earnings Presentation Q3 2025 SEI Earnings Presentation Safe Harbor Statement This presentation contains forward-looking statements within the meaning or the rules and regulations of the Securities and Exchange Commission. In some cases you can identify forward-looking statements by terminology, such as "may," "will," "expect," "believe," "remain" and "continue" or "appear." Our forward-looking statements include our current expectations as to: You should not place undue reliance on our forward-look ...

FY25 Financial Performance - Net sales reached $620 million, a 5% increase compared to $590.6 million in FY24 [12] - Gross margin improved to 55.1%, a 170 basis points increase from 53.4% in FY24 [12] - Operating income grew by 8% to $103.8 million, up from $96.4 million in FY24 [12] - Net income saw a significant increase of 31% to $91 million, compared to $69.6 million in FY24, which includes a one-time tax income adjustment of $11.9 million [12] - Diluted EPS also increased by 31% to $6.69, up from $5.11 in FY24, which includes a one-time income tax adjustment of $0.87 [12] Q4 FY25 Financial Performance - Net sales increased by 5% to $163.5 million, compared to $156 million in Q4 FY24 [26] - Gross margin increased by 60 basis points to 54.7%, up from 54.1% in Q4 FY24 [26] - Operating income rose by 17% to $28 million, compared to $24.1 million in Q4 FY24 [26] - Net income increased by 27% to $21.2 million, up from $16.8 million in Q4 FY24 [26] - Diluted EPS increased by 27% to $1.56, up from $1.23 in Q4 FY24 [26] Segment Performance (FY25) - Americas segment sales increased by 3% and accounted for 47% of global net sales [15] - EIMEA segment sales increased by 7% and accounted for 38% of global net sales [20] - Asia-Pacific segment sales increased by 6% and accounted for 15% of global net sales [23] FY26 Guidance (Pro Forma) - Sales growth is projected to be between 5% and 9%, leading to net sales between $630 million and $655 million [70] - Gross margin is expected to be between 55.5% and 56.5% [70] - Diluted EPS is projected to be between $5.75 and $6.15, based on 13.4 million shares outstanding [70]

Financial Performance Highlights - Net interest income increased by $184 million QoQ, driven by LHI growth and higher LHI excl MF9 yields[36] - Net interest margin expanded by 12bps QoQ[36] - Adjusted non-interest expense increased $05 million YoY to $1906 million[41] - YTD net interest income increased 13% despite a 125bps reduction in short-term rates[41] Balance Sheet Trends - Total deposit balances increased $14 billion or 6% QoQ[25] - Average non-interest bearing deposits, excluding MF9, increased $67 million or 2% QoQ to $34 billion[26] - Average MF9 non-interest bearing deposits declined $11 billion YoY to $49 billion, representing 90% of average mortgage finances loans in Q3 2025 compared to 116% in Q3 of last year[26] - Total LHI excl mortgage finance increased $14 billion or 8% YoY[16] Asset Quality - Total ACL, excl MF9 increased to $3238 million[50] - Criticized LHI declined $368 million or 41% YoY, with the percentage of total LHI declining 184bps to 219%[50] - Special mention LHI declined $90 million or 27% QoQ[50] Capital Position - Tangible book value per share increased by $288 or 4% QoQ to $7302[54] - Repurchased 87 thousand shares in Q3 for a total of $7 million[54] - Total capital ratio of 1610% and CET1 ratio of 1214%[54]

October 22, 2025 3 rd Quarter Earnings Alcoa Corporation 1 Cautionary Statement regarding Forward-Looking Statements This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include those containing such words as "aims," "ambition," "anticipates," "believes," "could," "develop," "endeavors," "estimates," "expects," "forecasts," "g ...

3Q25 Earnings Presentation October 22, 2025 Singapore: 3 Forward Looking Statements This presentation contains forward-looking statements made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include the discussions of our business strategies and expectations concerning future operations, margins, profitability, liquidity and capital resources. In addition, in certain portions included in this presentation, the words "anticipate ...

Financial Performance - Ribbon Communications' Q3 2025 revenue reached $215 million, a 2% year-over-year increase[15] - The company's gross margin for Q3 2025 was 53%[15] - Adjusted EBITDA for Q3 2025 was $29 million, a 3% decrease year-over-year[15] - The adjusted EBITDA margin for Q3 2025 was 13%, down 80 basis points year-over-year[15] - For the year-to-date 2025, revenue was $617 million, a 6% increase year-over-year[15] - Year-to-date adjusted EBITDA was $67 million, a 5% increase year-over-year, with an 11% margin[15] Segment Performance - IP Optical Networks revenue was $91 million in Q3 2025, an 11% increase year-over-year[22] - Cloud & Edge revenue was $124 million in Q3 2025, a 3% decrease year-over-year[27] Outlook - The company projects revenue between $230 million and $250 million for Q4 2025[49] - The company projects revenue between $847 million and $867 million for the full year 2025[49]

VTX3232 Phase 2 Trial Results - VTX3232 demonstrated statistically significant decrease in hsCRP of up to 80% within the first week of treatment[11] - A majority of participants achieved hsCRP levels of <2 mg/L at Week 12, a critical threshold for determining CV risk[11] - VTX3232 induced rapid and durable reductions in hsCRP, with ~80% decrease after 1 week of treatment sustained through Week 12[28, 31] - In the modified analysis set, a significant proportion of participants on VTX3232 had hsCRP of <2 mg/L at Week 12[37] - VTX3232 reduces IL-6 levels below CV risk threshold while maintaining immune homeostasis[45] - VTX3232 also Reduced Lipoprotein(a), Fibrinogen, and ESR[46] - VTX3232 decreased liver inflammation at Week 12, with greater effects observed when combined with semaglutide in participants with ≥ 5% baseline liver fat[55] Safety and Tolerability - VTX3232 was safe and well-tolerated in the Phase 2 study, with rates of adverse events comparable to placebo[11, 58] - There was no evidence of increased risk of infection with VTX3232[58] Market Opportunity - There is a vast market opportunity for residual inflammation reduction in CVD, with tens of millions of CV patients globally with residual inflammatory risk[60]